Sulbactam/cefoperazone is generally well tolerated. The majority of adverse events are of mild or moderate severity and are tolerated with continued treatment. The following ADRs were observed in clinical trials (comparative and non-comparative studies) and in the post-marketing.
All ADRs listed in the label are presented by MedDRA SOC and are presented in the order of clinical importance. (See Table 5).
Click on icon to see table/diagram/image